SK280137B6 - Deriváty 11-benzaldoxím-4,9-estradiénu, spôsob ich - Google Patents

Deriváty 11-benzaldoxím-4,9-estradiénu, spôsob ich Download PDF

Info

Publication number: SK280137B6
Authority: SK; Slovakia
Prior art keywords: radical; carbon atoms; alkyl; phenyl; estradien
Prior art date: 1993-09-20

Application number

SK957-94A

Other languages

English (en)

Slovak (sk)

Other versions

SK95794A3 (en

Inventor

Gerd Schubert

G�Nther Kaufmann

Lothar Sobeck

Michael Oettel

Walter Elger

Anatoli Kurischko

Original Assignee

Jenapharm Gmbh & Co. Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-20

Filing date

1994-08-10

Publication date

1999-08-06

1994-08-10 Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg

1995-04-12 Publication of SK95794A3 publication Critical patent/SK95794A3/sk

1999-08-06 Publication of SK280137B6 publication Critical patent/SK280137B6/sk

Links

238000002360 preparation method Methods 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
230000008569 process Effects 0.000 title claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 74
150000001875 compounds Chemical class 0.000 claims abstract description 65
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 42
125000000217 alkyl group Chemical group 0.000 claims abstract description 38
125000003118 aryl group Chemical group 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 21
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 18
125000002252 acyl group Chemical group 0.000 claims abstract description 10
125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 5
150000001342 alkaline earth metals Chemical group 0.000 claims abstract description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
-1 alkyl radical Chemical class 0.000 claims description 118
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 53
150000003254 radicals Chemical class 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 16
239000000460 chlorine Chemical group 0.000 claims description 14
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 13
238000006243 chemical reaction Methods 0.000 claims description 13
229910052794 bromium Inorganic materials 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 9
229910052731 fluorine Inorganic materials 0.000 claims description 9
125000001153 fluoro group Chemical group F* 0.000 claims description 8
239000011737 fluorine Substances 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
229910052740 iodine Chemical group 0.000 claims description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 5
229910052783 alkali metal Inorganic materials 0.000 claims description 5
150000001340 alkali metals Chemical group 0.000 claims description 5
KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical group [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 3
150000005840 aryl radicals Chemical class 0.000 claims description 3
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
125000001246 bromo group Chemical group Br* 0.000 claims 1
125000001309 chloro group Chemical group Cl* 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
125000002346 iodo group Chemical group I* 0.000 claims 1
JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 claims 1
125000001424 substituent group Chemical group 0.000 abstract 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 76
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 44
239000002904 solvent Substances 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
230000002829 reductive effect Effects 0.000 description 28
239000000243 solution Substances 0.000 description 24
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 22
239000000186 progesterone Substances 0.000 description 22
229960003387 progesterone Drugs 0.000 description 22
230000000694 effects Effects 0.000 description 21
239000011541 reaction mixture Substances 0.000 description 21
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
229910052938 sodium sulfate Inorganic materials 0.000 description 17
235000011152 sodium sulphate Nutrition 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
210000004027 cell Anatomy 0.000 description 16
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 16
239000012043 crude product Substances 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
239000012044 organic layer Substances 0.000 description 15
238000002211 ultraviolet spectrum Methods 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
239000010410 layer Substances 0.000 description 13
239000006260 foam Substances 0.000 description 12
230000035935 pregnancy Effects 0.000 description 12
239000003418 antiprogestin Substances 0.000 description 11
239000013078 crystal Substances 0.000 description 11
238000002844 melting Methods 0.000 description 11
230000008018 melting Effects 0.000 description 11
230000007935 neutral effect Effects 0.000 description 11
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
102000003998 progesterone receptors Human genes 0.000 description 10
108090000468 progesterone receptors Proteins 0.000 description 10
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
238000012746 preparative thin layer chromatography Methods 0.000 description 9
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
230000027455 binding Effects 0.000 description 8
229940011871 estrogen Drugs 0.000 description 8
239000000262 estrogen Substances 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
239000000126 substance Substances 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
241000700159 Rattus Species 0.000 description 7
239000002585 base Substances 0.000 description 7
102000015694 estrogen receptors Human genes 0.000 description 7
108010038795 estrogen receptors Proteins 0.000 description 7
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
150000007522 mineralic acids Chemical class 0.000 description 7
150000007524 organic acids Chemical class 0.000 description 7
239000007858 starting material Substances 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000005903 acid hydrolysis reaction Methods 0.000 description 6
150000001299 aldehydes Chemical class 0.000 description 6
229960003957 dexamethasone Drugs 0.000 description 6
230000016087 ovulation Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
108010042606 Tyrosine transaminase Proteins 0.000 description 5
230000002800 anti-glucocorticoid effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
239000003814 drug Substances 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
238000002156 mixing Methods 0.000 description 5
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
241000282898 Sus scrofa Species 0.000 description 4
102000016540 Tyrosine aminotransferases Human genes 0.000 description 4
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000000172 cytosol Anatomy 0.000 description 4
230000006870 function Effects 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000700 radioactive tracer Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000013558 reference substance Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
201000009273 Endometriosis Diseases 0.000 description 3
102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
102000006771 Gonadotropins Human genes 0.000 description 3
108010086677 Gonadotropins Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000000380 anti-gestagenic effect Effects 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000008298 dragée Substances 0.000 description 3
238000006266 etherification reaction Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000002622 gonadotropin Substances 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
239000000583 progesterone congener Substances 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
TWFNGPDYMFEHOB-UHFFFAOYSA-N 1-bromo-4-(dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=C(Br)C=C1 TWFNGPDYMFEHOB-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
229960002903 benzyl benzoate Drugs 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
231100000546 inhibition of ovulation Toxicity 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000035800 maturation Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960003248 mifepristone Drugs 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000000754 myometrium Anatomy 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000044 progesterone antagonist Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000012360 testing method Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
IYFRCKYESFJHMU-CQRWOGKFSA-N (5r,8s,11r,13s,14s)-11-[4-(dimethoxymethyl)phenyl]-5-hydroxy-3,3-dimethoxy-13-methyl-2,4,6,7,8,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-one Chemical compound C1=CC(C(OC)OC)=CC=C1[C@@H]1C2=C3CCC(OC)(OC)C[C@]3(O)CC[C@H]2[C@H](CCC2=O)[C@]2(C)C1 IYFRCKYESFJHMU-CQRWOGKFSA-N 0.000 description 1
INJBMNNLSBCVGV-QDWSJHPCSA-N (8r,9r,10s,13r)-13-methyl-2,4,5,6,7,8,9,10,11,12-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]12)CC(=O)CC1CC[C@@H]1[C@@H]2CC[C@@]2(C)C1=CC=C2 INJBMNNLSBCVGV-QDWSJHPCSA-N 0.000 description 1
NFKMXAPUXNJZIW-UKKFODGLSA-N (9R,10S,13S)-13-benzyl-1,2,3,4,5,6,9,10,11,12-decahydrocyclopenta[a]phenanthrene Chemical class C1(=CC=CC=C1)C[C@@]12C=CC=C1C1=CCC3CCCC[C@@H]3[C@H]1CC2 NFKMXAPUXNJZIW-UKKFODGLSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
BALGGARULZWYJB-UHFFFAOYSA-N 2-prop-1-ynoxyoxane Chemical compound CC#COC1CCCCO1 BALGGARULZWYJB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
235000003092 Artemisia dracunculus Nutrition 0.000 description 1
240000001851 Artemisia dracunculus Species 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010069941 DNA receptor Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000003747 Grignard reaction Methods 0.000 description 1
102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
201000004458 Myoma Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
QISHAXCKJVPZIZ-PWGAQZMISA-N ON=CC1=CC=CC=C1.C1CC2=CCCCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 Chemical class ON=CC1=CC=CC=C1.C1CC2=CCCCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 QISHAXCKJVPZIZ-PWGAQZMISA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical class C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000002513 anti-ovulatory effect Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
238000003398 chloramphenicol acetyltransferase induction Methods 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000013016 damping Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000003152 gestagenic effect Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
150000002443 hydroxylamines Chemical class 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000004220 muscle function Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
229950011093 onapristone Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000000624 ovulatory effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229940075065 polyvinyl acetate Drugs 0.000 description 1
230000000136 postovulatory effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
LBOHISOWGKIIKX-UHFFFAOYSA-M potassium;2-methylpropanoate Chemical compound [K+].CC(C)C([O-])=O LBOHISOWGKIIKX-UHFFFAOYSA-M 0.000 description 1
RWMKSKOZLCXHOK-UHFFFAOYSA-M potassium;butanoate Chemical compound [K+].CCCC([O-])=O RWMKSKOZLCXHOK-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000006259 progesterone secretion Effects 0.000 description 1
MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000002577 pseudohalo group Chemical group 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000027272 reproductive process Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
230000005070 ripening Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK957-94A 1993-09-20 1994-08-10 Deriváty 11-benzaldoxím-4,9-estradiénu, spôsob ich SK280137B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4332283A DE4332283A1 (de)	1993-09-20	1993-09-20	Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US08/309,175 US5693628A (en)	1993-09-20	1994-09-20	11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals containing these compounds

Publications (2)

Publication Number	Publication Date
SK95794A3 SK95794A3 (en)	1995-04-12
SK280137B6 true SK280137B6 (sk)	1999-08-06

Family

ID=25929786

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK957-94A SK280137B6 (sk)	1993-09-20	1994-08-10	Deriváty 11-benzaldoxím-4,9-estradiénu, spôsob ich

Country Status (16)

Country	Link
US (1)	US5693628A (fr)
EP (1)	EP0648778B1 (fr)
JP (1)	JP2753562B2 (fr)
AT (1)	ATE156835T1 (fr)
AU (1)	AU682195B2 (fr)
CA (1)	CA2130516C (fr)
CZ (1)	CZ292298B6 (fr)
DE (2)	DE4332283A1 (fr)
DK (1)	DK0648778T3 (fr)
ES (1)	ES2108371T3 (fr)
FI (1)	FI113657B (fr)
HU (1)	HU223339B1 (fr)
NO (1)	NO304989B1 (fr)
NZ (1)	NZ264229A (fr)
PL (1)	PL183181B1 (fr)
SK (1)	SK280137B6 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4332283A1 (de) *	1993-09-20	1995-04-13	Jenapharm Gmbh	Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) *	1993-09-20	1997-05-28	Jenapharm Gmbh	11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5576310A (en) *	1994-09-20	1996-11-19	Jenapharm Gmbh	11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
DE19548450A1 (de) *	1995-12-22	1997-06-26	Jenapharm Gmbh	17alpha-Cyanomethylestra-4,9-dien-3-on-17beta-yl- derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19745085A1 (de) *	1997-10-11	1999-04-15	Jenapharm Gmbh	11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) *	1998-03-03	1999-09-09	Jenapharm Gmbh	S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE19906152B4 (de)	1999-02-10	2005-02-10	Jenapharm Gmbh & Co. Kg	Wirkstoffhaltige Laminate für Transdermalsysteme
US8193252B1 (en)	1999-08-31	2012-06-05	Bayer Pharma AG	Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US7629334B1 (en)	1999-08-31	2009-12-08	Bayer Schering Pharma Aktiengesellschaft	Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
AR025457A1 (es) *	1999-08-31	2002-11-27	Schering Ag	Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
EA006805B1 (ru)	1999-08-31	2006-04-28	Шеринг Акциенгезельшафт	Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов
UA75339C2 (en) *	1999-08-31	2006-04-17	Schering Ag	Use of mesoprogestins (progesterone receptor modulators) as pharmaceutical components for manufacture of medicament for hormone replacement therapy (hrt)
DE19961219A1 (de) *	1999-12-15	2001-07-19	Jenapharm Gmbh	11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1157996A1 (fr) *	2000-05-23	2001-11-28	JENAPHARM GmbH	Nouveaux formes solides du mesoprogestin 11beta-(4E-(hxdroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
JP4593754B2 (ja) *	2000-10-13	2010-12-08	一般財団法人化学物質評価研究機構	化学物質の５０％阻害濃度決定方法
DE10056675A1 (de) *	2000-11-10	2002-05-16	Jenapharm Gmbh	Verfahren zur Herstellung von 4-(17alpha-Methylsubstituierten 3-Oxoestra-4,9-dien-11ß-yl)-benzaldehyd-(1E oder 1Z)-oximen
DE10056676A1 (de) *	2000-11-10	2002-05-16	Jenapharm Gmbh	Verfahren zur Herstellung von 4-/17alpha-substituierten-3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1E oder 1Z)-oximen
EP1285927A3 (fr) *	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Utilisation d'antagonistes du récepteur glucocorticoide pour la prévention et traitement des maladies de la fonction reproductive masculine
DE10218109A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10221034A1 (de)	2002-05-03	2003-11-20	Schering Ag	17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2004014935A1 (fr) *	2002-08-02	2004-02-19	Schering Aktiengesellschaft	Modulateurs de recepteurs de progesterone presentant une activite antigonadotrope augmentee, destines au controle de fertilite et au traitement hormonal substitutif chez la femme
DE10236405A1 (de) *	2002-08-02	2004-02-19	Schering Ag	Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20050215535A1 (en) *	2004-03-24	2005-09-29	Kristof Chwalisz	Sequential SPRM/progestin treatment
US20050215536A1 (en) *	2004-03-24	2005-09-29	Kristof Chwalisz	Sequential SPRM/ progestin treatment
DE102005059222B4 (de) *	2005-12-08	2007-10-11	Bayer Schering Pharma Ag	11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
DE102006018888A1 (de) *	2006-04-18	2007-10-25	Bayer Schering Pharma Ag	Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
ES2643318T3 (es)	2006-10-24	2017-11-22	Repros Therapeutics Inc.	Composiciones y métodos para suprimir la proliferación endometrial
DE102006054535A1 (de) *	2006-11-15	2008-05-21	Bayer Schering Pharma Aktiengesellschaft	Progesteronrezeptorantagonisten
TWI539953B (zh)	2008-04-28	2016-07-01	瑞波若斯治療學公司	用於治療乳癌之組成物和方法
DE102009034366A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de)	2009-07-21	2011-02-10	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102010007722A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
BR112012023281A2 (pt)	2010-03-22	2016-05-17	Repros Therapeutics Inc	composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
HK1246653A1 (zh)	2014-11-17	2018-09-14	Context Biopharma Inc.	奥那司酮延长释放组合物和方法
US10308676B2 (en)	2015-09-25	2019-06-04	Context Biopharma Inc.	Methods of making onapristone intermediates
EP3389632A4 (fr)	2015-12-15	2019-11-06	Context Biopharma Inc.	Compositions à base d'onapristone amorphe et leurs procédés de fabrication
US20180148471A1 (en)	2016-11-30	2018-05-31	Arno Therapeutics, Inc.	Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU580843B2 (en) *	1985-02-07	1989-02-02	Schering Aktiengesellschaft	11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) *	1985-02-22	1986-08-28	Schering AG, Berlin und Bergkamen, 1000 Berlin	11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) *	1986-05-06	1988-08-19	Roussel Uclaf	Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) *	1987-01-23	1993-12-21	Akzo N.V.	11-aryl steroid derivatives
EP0289073B1 (fr) *	1987-04-24	1991-11-27	Akzo N.V.	Dérivés de 11-arylestranes et 11-arylprégnanes
DD287510A5 (de) *	1989-04-19	1991-02-28	Adw,Zi Fuer Mikrobiologie Und Experimentelle Therapie,De	Verfahren zur herstellung von 17 alpha-ch tief 2x-substituierten 11 beta-aryl-4,9-diensteroiden
DE59010853D1 (de) *	1989-08-04	1998-12-03	Schering Ag	11 Beta-Aryl-gona-4,9-dien-3-one
US5276023A (en) *	1989-08-08	1994-01-04	Roussel Uclaf	19-nor-steroid esters
DD289539A5 (de) *	1989-10-12	1991-05-02	Zi F. Mikrobiologie U. Experimentelle Therapie,De	Verfahren zur herstellung von 11 beta-(4-acetylphenyl)-17alpha-alkoxy-methyl-estra-4,9-dien-3-onen
US5407928A (en) *	1990-08-15	1995-04-18	Schering Aktiengesellschaft	11β-aryl-gona-4,9-dien-3-ones
DE4332284C2 (de) *	1993-09-20	1997-05-28	Jenapharm Gmbh	11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) *	1993-09-20	1995-04-13	Jenapharm Gmbh	Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5576310A (en) *	1994-09-20	1996-11-19	Jenapharm Gmbh	11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds

1993
- 1993-09-20 DE DE4332283A patent/DE4332283A1/de not_active Withdrawn
1994
- 1994-07-07 EP EP94250178A patent/EP0648778B1/fr not_active Expired - Lifetime
- 1994-07-07 ES ES94250178T patent/ES2108371T3/es not_active Expired - Lifetime
- 1994-07-07 AT AT94250178T patent/ATE156835T1/de not_active IP Right Cessation
- 1994-07-07 DK DK94250178.4T patent/DK0648778T3/da active
- 1994-07-07 DE DE59403717T patent/DE59403717D1/de not_active Expired - Fee Related
- 1994-08-09 FI FI943687A patent/FI113657B/fi active
- 1994-08-09 NO NO942953A patent/NO304989B1/no not_active IP Right Cessation
- 1994-08-10 SK SK957-94A patent/SK280137B6/sk not_active IP Right Cessation
- 1994-08-12 NZ NZ264229A patent/NZ264229A/en not_active IP Right Cessation
- 1994-08-15 CZ CZ19941970A patent/CZ292298B6/cs not_active IP Right Cessation
- 1994-08-18 AU AU70350/94A patent/AU682195B2/en not_active Ceased
- 1994-08-19 CA CA002130516A patent/CA2130516C/fr not_active Expired - Lifetime
- 1994-09-19 PL PL94305092A patent/PL183181B1/pl not_active IP Right Cessation
- 1994-09-19 HU HU9402694A patent/HU223339B1/hu not_active IP Right Cessation
- 1994-09-20 US US08/309,175 patent/US5693628A/en not_active Expired - Lifetime
- 1994-09-20 JP JP6224379A patent/JP2753562B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE156835T1 (de)	1997-08-15
NO942953D0 (no)	1994-08-09
NZ264229A (en)	1995-04-27
JP2753562B2 (ja)	1998-05-20
NO942953L (no)	1995-03-21
CZ197094A3 (en)	1995-04-12
HU223339B1 (hu)	2004-06-28
FI943687A0 (fi)	1994-08-09
DE59403717D1 (de)	1997-09-18
NO304989B1 (no)	1999-03-15
PL183181B1 (pl)	2002-06-28
SK95794A3 (en)	1995-04-12
EP0648778B1 (fr)	1997-08-13
JPH07149789A (ja)	1995-06-13
DK0648778T3 (da)	1998-03-30
DE4332283A1 (de)	1995-04-13
EP0648778A2 (fr)	1995-04-19
CZ292298B6 (cs)	2003-09-17
HUT68029A (en)	1995-05-29
FI113657B (fi)	2004-05-31
ES2108371T3 (es)	1997-12-16
EP0648778A3 (fr)	1995-08-09
PL305092A1 (en)	1995-04-03
CA2130516C (fr)	2003-04-15
AU682195B2 (en)	1997-09-25
US5693628A (en)	1997-12-02
AU7035094A (en)	1995-03-30
HU9402694D0 (en)	1994-11-28
CA2130516A1 (fr)	1995-03-21
FI943687L (fi)	1995-03-21

Legal Events

Date	Code	Title	Description
2011-05-06	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20100810

Publication	Publication Date	Title
FI113657B (fi)	2004-05-31	Menetelmä uusien 11beeta-bentsaldoksiimi-estra-4,9-dieeni-johdannaisten valmistamiseksi käytettäväksi farmaseuttisissa koostumuksissa
US4774236A (en)	1988-09-27	17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
EP2039701B1 (fr)	2014-04-23	20-céto-11Beta-Arylstéroides et leurs Dérivés possedant des propriétés hormonales d'agoniste ou d'antagoniste
RU2130944C1 (ru)	1999-05-27	ПРОИЗВОДНЫЕ β БЕНЗАЛЬДОКСИМ-ЭСТРА-4,9-ДИЕНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US4861763A (en)	1989-08-29	17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US5576310A (en)	1996-11-19	11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
BG64735B1 (bg)	2006-01-31	S-заместени тиолови естери на 11бета-бензалдоксим-естра-4,9-диен-въглеродна киселина, метод за тяхното получаване и фармацевтични препарати, съдържащи тези съединения
RU2137777C1 (ru)	1999-09-20	ПРОИЗВОДНЫЕ 11β-БЕНЗАЛЬДОКСИМ-ЭСТРА-4,9-ДИЕНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
PT1219632E (pt)	2006-12-29	Esteróides, sua preparação, suas composições farmacológicas e uso dos composto
DE19961219A1 (de)	2001-07-19	11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
SK19492000A3 (sk)	2001-09-11	17-halognovan 19-nor steroidy, spsob ich prpravy a medziprodukty, ich pouitie a farmaceutick prostriedky, ktor ich obsahuj
IE910727A1 (en)	1991-09-11	New use of anti-progestomimetic compounds in breeding¹animals
CA2614667C (fr)	2012-05-22	20-ceto-11b-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste
HK1124339B (en)	2015-08-28	20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal activity